What to know about jury duty in Delaware Here are some tips and information about what to do when you receive a jury summons in the mail in Delaware. Robert Higgins, 69, received a 65-year sentence for defrauding investors of $76 million in gold and silver. Prosecutors highlighted Higgins’ lavish lifestyle, funded by the stolen
The Green Bay City Council on June 10 denied renewing liquor and massage establishment licenses for a bar and seven massage parlors, respectively, based on violations spelled out in police memos. For one bar, however, the council went against the police department’s recommendation and approved the liquor license renewal. In the case of the massage
Best brunch in RI? Let The Providence Journal food critic guide you. Searching for French toast, mimosas, omelets and eggs benedict? Here are all the secret brunch spots you can’t miss in Providence Journal Staff Olneyville New York System has requested liquor licenses for its locations in Providence and Cranston, Rhode Island. The Providence Board
Trump’s tariff pause brings little relief as recession fears linger Donald Trump’s move to postpone most of his new tariffs for 90 days seems to have brought only fleeting relief for markets. After a huge rally on April 10, April 11 saw Asian stocks head lower again. KPERS saw a small gain in Q1 2025
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Cash, cash equivalents and marketable securities of $197.9 million as of March 31, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call
Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025 FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in mid-2025 after our planned Type B meeting with the FDA Ended the
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to provide interim analysis data for approximately 50 patients with at least 18 weeks of follow-up Cash,
– Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization – – Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively – – Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company